Egfl6 specific monoclonal antibodies and methods of their use

Patent metadata

Field	Value
Publication number	US-2025145702-A1
Application number	US-202418920268-A
Country	US
Kind code	A1
Filing date	Oct 18, 2024
Priority date	Feb 5, 2016
Publication date	May 8, 2025
Grant date	—

Abstract

Isolated or recombinant anti-EGFL6 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.

First claim

1 - 55 . (canceled)

56 . One or more polynucleotide molecules encoding an antibody or antigen-binding fragment thereof that specifically binds to epidermal growth factor-like domain-containing protein 6 (EGFL6) and comprises:
(a) a V H CDR1 identical to SEQ ID NO: 64; (b) a V H CDR2 identical to SEQ ID NO:65; (c) a V H CDR3 identical to SEQ ID NO: 66; (d) a V L CDR1 identical to SEQ ID NO: 126; (e) a V L CDR2 identical to SEQ ID NO: 127; and (f) a V L CDR3 identical to SEQ ID NO: 128.

57 . The one or more polynucleotide molecules of claim 56 , wherein the antibody or antigen binding fragment thereof comprises a V H domain at least about 80% identical to SEQ ID NO: 177; and a V L domain at least about 80% identical to SEQ ID NO: 178.

58 . The one or more polynucleotide molecules of claim 56 , wherein the antibody or antigen-binding fragment is an IgG.

59 . The one or more polynucleotide molecules of claim 56 , wherein the antibody or antigen-binding fragment is an Fab′, an F(ab′) 2 , an F(ab′) 3 , a monovalent scFv, or a bivalent scFv.

60 . The one or more polynucleotide molecules of claim 56 , wherein the antibody or antigen binding fragment thereof comprises a V H domain identical to SEQ ID NO: 177 and a V L domain identical to SEQ ID NO: 178.

61 . The one or more polynucleotide molecules of claim 56 , wherein the one or more polynucleotide molecules are comprised within an expression vector.

62 . A cell comprising the one or more polynucleotide molecules of claim 56 .

63 . The cell of claim 62 , wherein the cell is selected from the group consisting of a mammalian cell, a yeast cell, a bacterial cell, and an insect cell.

64 . A method of manufacturing an antibody or an antigen-binding fragment thereof, the method comprising expressing the one or more polynucleotide molecules of claim 56 in a cell and purifying the antibody from the cell.

Assignees

• Univ Texas

Inventors

• Zhang Ningyan
• An Zhiqiang
• Sood Anil K

Classifications

• G01N33/57545

  of the ovaries · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61P35/00

  Antineoplastic agents · CPC title